S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA
2009;301(1):39-51. http://www.ncbi.nlm.nih.gov/pubmed/19066370
14. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes
RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr.
The influence of finasteride on the development of prostate cancer. The New England
journal of medicine 2003;349(3):215-24. http://www.ncbi.nlm.nih.gov/pubmed/12824459
15. Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM,
Coltman CA. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol
2007;178(1):107-9. http://www.ncbi.nlm.nih.gov/pubmed/17499284
16. Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase
Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev 2008;(2):CD007091.
http://www.ncbi.nlm.nih.gov/pubmed/18425978
17. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Ballentine Carter H,
Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use
of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of
Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology
2009;27(9):1502-16. http://www.ncbi.nlm.nih.gov/pubmed/19252137
18. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J,
Holmberg E, Lilja H. Mortality results from the Goteborg randomised population-based
prostate-cancer screening trial. Lancet Oncol 2010;11(8):725-32.
http://www.ncbi.nlm.nih.gov/pubmed/20598634
19. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan
M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G,
Villers A, Rebillard X, van der KT, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A.
Screening and prostate-cancer mortality in a randomized European study. The New England
journal of medicine 2009;360(13):1320-8.
http://www.ncbi.nlm.nih.gov/pubmed/19297566
20. Andriole GL, Crawford ED, Grubb RL, III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann
EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Clapp JD, Rathmell JM, Riley TL,
Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD.
Mortality results from a randomized prostate-cancer screening trial. The New England
journal of medicine 2009;360(13):1310-9.
http://www.ncbi.nlm.nih.gov/pubmed/19297565
21. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer
screening trial: 20 year follow-up. BMJ 2011;342:d1539.
http://www.ncbi.nlm.nih.gov/pubmed/21454449
22. Labrie F, Candas B, Cusan L, Gomez JL, Belanger A, Brousseau G, Chevrette E, Levesque J.
Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec
prospective randomized controlled trial. Prostate 2004;59(3):311-8.
http://www.ncbi.nlm.nih.gov/pubmed/15042607
23. Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B, Dahm P.
Screening for prostate cancer: systematic review and meta-analysis of randomised
controlled trials. BMJ 2010;341:c4543. http://www.ncbi.nlm.nih.gov/pubmed/20843937
24. Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Schmid HP, van der Kwast
TH, Wiegel T, Zattoni F, European Association of Urology (EAU). EAU guidelines on prostate
cancer. Arnhem: EAU; 2011.
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011